Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.970
-0.030 (-3.00%)
Dec 20, 2024, 4:00 PM EST - Market closed

Akari Therapeutics, Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Net Income
-20.16-10.01-17.75-17.42-17.08-16.85
Upgrade
Depreciation & Amortization
0.010000.010.02
Upgrade
Stock-Based Compensation
1.291.150.740.310.331.05
Upgrade
Other Operating Activities
-1.18-6.71-5.320.24-0.15-0.23
Upgrade
Change in Accounts Payable
3.78-0.94-0.88-0.24-0.252.38
Upgrade
Change in Other Net Operating Assets
1.410.071.7-1.740.190.71
Upgrade
Operating Cash Flow
-14.84-16.43-21.5-18.85-16.95-12.92
Upgrade
Total Debt Issued
1.03-----
Upgrade
Total Debt Repaid
-0.88-----
Upgrade
Net Debt Issued (Repaid)
0.15-----
Upgrade
Issuance of Common Stock
12.217.0225.2914.2925.0712.65
Upgrade
Financing Cash Flow
12.357.0225.2914.2925.0712.65
Upgrade
Foreign Exchange Rate Adjustments
00.010.11-0.140.20.03
Upgrade
Net Cash Flow
-2.49-9.413.89-4.698.32-0.24
Upgrade
Free Cash Flow
-14.84-16.43-21.5-18.85-16.95-12.92
Upgrade
Free Cash Flow Per Share
-1.81-3.36-6.89-8.78-10.73-14.11
Upgrade
Levered Free Cash Flow
--16.74-6.04-11.31-11.96-6.69
Upgrade
Unlevered Free Cash Flow
--16.74-6.04-11.31-11.96-6.69
Upgrade
Change in Net Working Capital
-7.39-7.650.871.06-2.85
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.